Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Tadalafil (Primary) ; Nivolumab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 07 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top